Therapeutic equivalence? [Design Issues]

posted by Dr_Dan  – Germany, 2011-02-08 15:40 (5116 d 11:17 ago) – Posting: # 6593
Views: 5,907

Dear d_labes
not all anti-cancer drugs are cytotoxic, for example aromatase inhibitors for treating breast cancer or imatinib, a phenylaminopyrimidine derivative, which is a selective inhibitor of the tyrosine kinase activity of BCR-ABL fusion gene (oncoprotein), the product of the Philadelphia chromosome. You can test these drugs in healthy subjects, no problem. Other drugs like capecitabine or temozolomide can only be tested in patients. So it depends.
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,379 posts in 4,913 threads, 1,661 registered users;
132 visitors (0 registered, 132 guests [including 12 identified bots]).
Forum time: 02:58 CET (Europe/Vienna)

Statistics is the art of never having to say you’re wrong.
Variance is what any two statisticians are at.    C.J. Bradfield

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5